The Filing Desk

Atara Biotherapeutics vs Xencor

Atara Biotherapeutics ATRA · Xencor XNCR · Biotechnology

Xencor reported revenue of $126 million in fiscal 2025, about the same as Atara Biotherapeutics' $121 million in fiscal 2025. Atara Biotherapeutics' revenue fell 6.3% in its latest year, and Xencor's grew 13.7%. Atara Biotherapeutics had an operating margin of 29.7%, against -141.3% at Xencor. Free cash flow was −$51 million at Atara Biotherapeutics and −$138 million at Xencor.

Side by side

Atara BiotherapeuticsXencor
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$121M$126M
Revenue growth−6.3%13.7%
Revenue growth a year, last 5 years—0.5%
Gross margin——
Operating margin29.7%−141.3%
Net margin27.1%−73.2%
Free cash flow−$51M−$138M
Free cash flow margin−42.2%−110.1%
Return on capital—−19.9%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count69.8%14.1%
Last close$6.34$34.01
P/E at the last close——
Insider trades, last 12 monthsbought $5.7 million, sold $3.8 millionsold $7.4 million
Piotroski F-score—3 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Atara BiotherapeuticsXencor
Operating margin
Percent of revenue
Atara BiotherapeuticsXencor
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Atara BiotherapeuticsXencor

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Atara Biotherapeutics and Xencor pages.